Nantahala Capital Management, LLC - Jun 14, 2024 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)

Role
10%+ Owner
Signature
/s/ Taki Vasilakis, Chief Compliance Officer, Nantahala Capital Management, LLC
Stock symbol
AYTU
Transactions as of
Jun 14, 2024
Transactions value $
$0
Form type
4
Date filed
6/18/2024, 05:09 PM
Previous filing
Mar 21, 2024
Next filing
Nov 15, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AYTU Tranche B Warrant Exercise of in-the-money or at-the-money derivative security $0 -815K -100% $0.00* 0 Jun 14, 2024 Common Stock 815K $1.59 See Footnote F1, F2
transaction AYTU Exchange Warrants Exercise of in-the-money or at-the-money derivative security $0 +815K $0.00 815K Jun 14, 2024 Common Stock 815K $0.00 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million.
F2 Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Aytu BioPharma, Inc ("Issuer") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
F3 Subject to certain limits on beneficial ownership, the Exchange Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Exchange Warrants do not expire until exercised in full.